TORRENT PHARMA H-1B Visa Sponsorship & Salary Data

The median H-1B salary at TORRENT PHARMA is $114,438, based on 22 certified filings from FY 2020 to FY 2025. This is 5% lower than the national H-1B median salary of $120,000. Compensation at TORRENT PHARMA reflects their market positioning, with entry-level roles starting around $65,320 and senior positions reaching $198,450 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at TORRENT PHARMA range from $64,189 at the 10th percentile to $198,450 at the 90th percentile, showing a $134,261 spread across experience levels and roles. The 25th percentile is $65,320 and the 75th percentile is $145,225.

Yes, TORRENT PHARMA actively sponsors H-1B visas in FY 2025. In the most recent fiscal year (FY 2025), TORRENT PHARMA filed 2 H-1B labor condition applications with 2 certified and 0 denied, at a median salary of $198,450. Across FY 2020–2025, they have filed 22 total H-1B applications with 22 certified and a 0% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. TORRENT PHARMA sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2025), TORRENT PHARMA filed 2 H-1B applications, with 2 certified and 0 denied. Over 5 years of data, TORRENT PHARMA has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

TORRENT PHARMA's LCA (Labor Condition Application) denial rate is 0%, with 0 out of 22 applications denied across all years. This translates to a 100.0% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating TORRENT PHARMA as a potential H-1B sponsor.

This is an excellent approval rate, indicating TORRENT PHARMA has strong H-1B sponsorship practices and typically meets DOL requirements. Applicants can feel confident in the company's H-1B track record.

TORRENT PHARMA sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 22 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles TORRENT PHARMA most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at TORRENT PHARMA:

The most frequently sponsored role is Quality Control Chemist with 3 filings at a median salary of $65,320. This is followed by Regulatory Validation Associate (13-1041.07) (2 filings) and Senior Manager Cmo.

TORRENT PHARMA's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where TORRENT PHARMA sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top TORRENT PHARMA H-1B locations:

The largest H-1B hub for TORRENT PHARMA is Levittown, PA with 15 filings at a median salary of $106,800. The highest-paying location is Levittown,, PA at $300,000 median. Salaries range from $106,800 to $300,000 across office locations.

TORRENT PHARMA's median H-1B salary has increased by +73% from FY 2020 ($114,438) to FY 2025 ($198,450). Tracking salary trends over time reveals how TORRENT PHARMA adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at TORRENT PHARMA.

Year-by-year breakdown:

• FY 2020: $114,438 (11 certified)
• FY 2021: $65,320 (5 certified)
• FY 2022: $180,000 (3 certified)
• FY 2023: $145,225 (1 certified)
• FY 2025: $198,450 (2 certified)

This 73% growth reflects strong compensation adjustments at TORRENT PHARMA, keeping pace with market demands for H-1B talent.

TORRENT PHARMA primarily files H-1B applications at Wage Level IV, accounting for 32% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making TORRENT PHARMA's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

TORRENT PHARMA has a mix of entry-level (Level I) and experienced (Level II+) H-1B positions. This reflects a range of roles from junior to senior.

TORRENT PHARMA's median H-1B salary of $114,438 is 5% lower than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating TORRENT PHARMA's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare TORRENT PHARMA's offerings with similar companies in your field for a more accurate assessment.

TORRENT PHARMA's H-1B salaries are competitive with industry averages. The 22 total filings indicate active H-1B sponsorship.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. TORRENT PHARMA's higher proportion of Level III-IV positions (59%) may benefit from wage-based lottery prioritization.

With 22 certified filings, TORRENT PHARMA invests significantly in H-1B sponsorship. The company's 0% denial rate suggests strong compliance with H-1B requirements and documentation standards.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.